GENFIT unveils its future clinical trials and expectations for 2025

GENFIT, a biopharmaceutical company, has presented details of its upcoming clinical trials focused on Acute on-Chronic Liver Failure (ACLF), with two new trials planned for early 2025. In parallel, results from three studies, including the Phase 2 UNVEIL-IT® trial, are expected by the end of 2025.

Pascal Prigent, CEO, highlighted that these efforts are based on real-world data and the analysis of 270,000 patients. The chosen approaches should facilitate rapid patient recruitment. The results of ongoing studies, including one evaluating GNS561 for cholangiocarcinoma, will be crucial for progress in the coming years.

The foundations of this strategy include detailed analysis of real-world data and collaborations with academic experts. These elements enable rapid dynamics in the evaluation of drug candidates while reducing risks for future investments.